Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of cardiovascular-focused biotechnology company Amarin (NASDAQ:AMRN) dipped as much as 13% earlier in the trading session after more question marks were raised regarding the marketing exclusivity of Vascepa, its FDA-approved triglyceride reducing drug that, when used in combination with proper diet and exercise, can reduce the risk of heart attack and/or stroke.
So what: In an 8-K released this morning, Amarin noted that it's still awaiting word from the FDA regarding the new chemical entity, or NCE, status of Vascepa. At stake for Amarin is whether or not Vascepa will receive marketing exclusivity for a length of five years. As with all drugs, exclusivity is expected, but not necessarily always granted by the FDA, and that's the primary cause for today's drop.
Now what: I wouldn't completely overreact based on today's 8-K filing if I were an Amarin shareholder, as a delay in an NCE ruling isn't completely uncommon -- but admittedly, shareholders are starting to sweat. The key point here is that Amarin remains a prime takeover target in the biotech sector, and, assuming it finds a solid marketing partner (and trust me, there's no shortage of big pharmaceutical companies with declining pipelines that'd love to get their hands on Vascepa's revenue stream), the long-term future for Amarin remains bright.
Craving more input? Start by adding Amarin to your free and personalized Watchlist so you can keep up on the latest news with the company.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.